RemeGen's telitacicept helps improve myasthenia gravis severity in phase 2 trial

Nov. 01, 2022 5:38 AM ETRemegen Co Ltd. ADR (REGMY), REGMFBy: Ravikash, SA News Editor

Myasthenia Gravis awareness month is June.

Anna Altenburger

  • RemeGen (OTCPK:REGMF) (OTCPK:REGMY) said its novel fusion protein telitacicept help reduce the severity of symptoms in Chinese patients with myasthenia gravis (MG) in a phase 2 trial.
  • MG is an autoimmune neuromuscular disorder mainly characterized by muscle weakness and

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.